In the latest trading session, 2.09 million ImmunityBio Inc (NASDAQ:IBRX) shares changed hands as the company’s beta touched 0.93. With the company’s most recent per share price at $3.78 changed hands at -$0.23 or -5.86% at last look, the market valuation stands at $2.63B. IBRX’s current price is a discount, trading about -178.57% off its 52-week high of $10.53. The share price had its 52-week low at $1.25, which suggests the last value was 66.93% up since then. When we look at ImmunityBio Inc’s average trading volume, we note the 10-day average is 3.76 million shares, with the 3-month average coming to 3.35 million.
Analysts gave the ImmunityBio Inc (IBRX) stock a consensus recommendation rating of Sell, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 1 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IBRX as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. ImmunityBio Inc’s EPS for the current quarter is expected to be -0.16.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunityBio Inc (NASDAQ:IBRX) trade information
Instantly IBRX was in red as seen in intraday trades today. With action -14.59%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -24.80%, with the 5-day performance at -14.59% in the red. However, in the 30-day time frame, ImmunityBio Inc (NASDAQ:IBRX) is -34.80% down. Looking at the short shares, we see there were 46.77 million shares sold at short interest cover period of 23.13 days.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 52.75% from its recent market value. According to analyst projections, IBRX’s forecast low is 8 with 8 as the target high. To hit the forecast high, the stock’s price needs a -111.64% plunge from its current level, while the stock would need to soar -111.64% for it to hit the projected low.
ImmunityBio Inc (IBRX) estimates and forecasts
Data shows that the ImmunityBio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -22.16% over the past 6 months, a 24.24% in annual growth rate that is considerably higher than the industry average of 18.00%. Year-over-year growth is forecast to reach 11,403.20% up from the last financial year.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 10.03M. 1 analysts are of the opinion that ImmunityBio Inc’s revenue for the current quarter will be 22.74M. The company’s revenue for the corresponding quarters a year ago was 82k and 139k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 12,131.70%. The estimates for the next quarter sales put growth at 16,259.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.17%. The 2024 estimates are for ImmunityBio Inc earnings to increase by 25.22%, but the outlook for the next 5-year period is at -1.70% per year.
IBRX Dividends
ImmunityBio Inc is expected to release its next quarterly earnings report in September.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 77.04% of ImmunityBio Inc shares while 9.12% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 39.73%. There are 9.12% institutions holding the ImmunityBio Inc stock share, with STATE STREET CORP the top institutional holder. As of 2024-03-31, the company held 2.7887% of the shares, roughly 14.18 million IBRX shares worth $76.17 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 2.6619% or 13.54 million shares worth $72.71 million as of 2024-03-31.
Among Mutual Funds, the top two as of Jun 30, 2024 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 4.38 shares estimated at $16.43 million under it, the former controlled 0.63% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 0.60% of the shares, roughly 4.2 shares worth around $15.77 million.
